Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab and Durvalumab with or without Radiation in Relapsed SCLC
NCT02701400Phase 2Completed
- Sponsor
- Emory University
- Start
- Apr 2016
- Primary completion
- Aug 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in Small Cell Lung Cancer (SCLC), sponsored by Emory University. Started Apr 2016; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
Small Cell Lung Cancer (SCLC)
Beyond the preview
Go deeper on NCT02701400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02701400.